The clearance shores up the competitive position for Omvoh (mirikizumab) in the increasingly competitive inflammatory bowel disease ... (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease ... for the inflammatory bowel disease (IBD). Tremfya (guselkumab) is also the only ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Chronic inflammatory bowel disease is challenging to treat and carries a risk of complications, including the development of bowel cancer. Young people are particularly affected: when genetic ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

There have been important recent advances in the management of Crohn's disease, including new classes of biological or small molecule therapies, an appreciation that endoscopic mucosal healing results ...

Results from a new study show that treatment with allogeneic mesenchymal stem cells (MSCs) leads to a greater remission rate than placebo in patients with treatment-refractory perianal fistulas ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease, according to findings published in Science Immunology. The ...

Crohn s disease is a chronic inflammatory disease of the gastrointestinal tract, mostly affecting the ileum. The inflammation can extend through the intestinal wall and tends to be asymmetric and ...